Loading
Two cycles of ABVD chemotherapy and a lower radiotherapy dose cured early favourable Hodgkin lymphoma as well as four cycles and a higher dose, so patients could be given less treatment and fewer late effects.
German Hodgkin Study Group randomised 2 by 2 trial of 1,370 patients with early-stage favourable Hodgkin lymphoma comparing four with two cycles of ABVD and involved-field radiotherapy of 30 Gy with 20 Gy.
Five-year freedom from treatment failure and overall survival were about 93 percent and 97 percent with no differences between arms, while toxicity was lower with the reduced treatment. Two cycles of ABVD followed by 20 Gy became a standard for early favourable disease.
Patients with early favourable Hodgkin lymphoma are cured with two cycles of ABVD and 20 Gy of involved-site radiotherapy; later trials tested whether PET can spare radiotherapy altogether.
Shares Dacarbazine, Vinblastine, Early-stage classical Hodgkin lymphoma (stage I to II), Doxorubicin.
Shares Dacarbazine, Vinblastine, Early-stage classical Hodgkin lymphoma (stage I to II), Doxorubicin.
Shares Dacarbazine, Vinblastine, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Doxorubicin.
Shares Dacarbazine, Vinblastine, Doxorubicin, Hodgkin lymphoma.
Shares Dacarbazine, Vinblastine, Doxorubicin, Hodgkin lymphoma.
Shares GHSG HD10, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, Dacarbazine, Vinblastine.
Shares GHSG HD10, Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting, Hodgkin lymphoma.
Shares Positron emission tomography-guided treatment in early-stage favorable Hodgkin lymphoma: final results of the international, randomized phase III HD16 trial by the German Hodgkin Study Group, Dacarbazine, Vinblastine, Early-stage classical Hodgkin lymphoma (stage I to II).